OneDigital Investment Advisors LLC Sells 441 Shares of IQVIA Holdings Inc. (NYSE:IQV)

OneDigital Investment Advisors LLC decreased its position in IQVIA Holdings Inc. (NYSE:IQV) by 3.0% in the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 14,436 shares of the medical research company’s stock after selling 441 shares during the period. OneDigital Investment Advisors LLC’s holdings in IQVIA were worth $3,421,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. PGGM Investments boosted its holdings in shares of IQVIA by 55.8% in the second quarter. PGGM Investments now owns 12,073 shares of the medical research company’s stock valued at $2,553,000 after purchasing an additional 4,326 shares during the period. Quadrature Capital Ltd purchased a new stake in IQVIA during the first quarter worth $3,365,000. Raymond James & Associates lifted its holdings in IQVIA by 0.7% during the second quarter. Raymond James & Associates now owns 800,374 shares of the medical research company’s stock worth $169,231,000 after buying an additional 5,417 shares during the period. UniSuper Management Pty Ltd lifted its holdings in IQVIA by 253.0% during the first quarter. UniSuper Management Pty Ltd now owns 6,029 shares of the medical research company’s stock worth $1,525,000 after buying an additional 4,321 shares during the period. Finally, Versor Investments LP purchased a new stake in IQVIA during the third quarter worth $1,328,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Price Performance

Shares of IQV opened at $192.63 on Friday. The business’s 50-day moving average is $227.96 and its two-hundred day moving average is $228.59. The company has a market capitalization of $34.96 billion, a P/E ratio of 25.28, a P/E/G ratio of 2.17 and a beta of 1.51. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. IQVIA Holdings Inc. has a fifty-two week low of $189.63 and a fifty-two week high of $261.73.

Insiders Place Their Bets

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the sale, the insider now directly owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. This trade represents a 6.24 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 1.60% of the stock is owned by insiders.

Analyst Ratings Changes

A number of analysts have weighed in on IQV shares. Truist Financial lowered their target price on IQVIA from $286.00 to $265.00 and set a “buy” rating for the company in a report on Monday, November 4th. BTIG Research decreased their price objective on IQVIA from $290.00 to $260.00 and set a “buy” rating for the company in a report on Friday, November 1st. TD Cowen decreased their price objective on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a report on Friday, November 1st. UBS Group increased their price objective on IQVIA from $295.00 to $300.00 and gave the company a “buy” rating in a report on Tuesday, July 23rd. Finally, Evercore ISI decreased their price objective on IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Five research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $259.13.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.